RATIONALE: Bone marrow (BM)-derived cells have been implicated in pulmonary fibrosis. However, their precise role in pathogenesis is incompletely understood. OBJECTIVES: To elucidate roles of BM-derived cells in bleomycin-induced pulmonary fibrosis, and clarify their potential relationship to lung hematopoietic progenitor cells (LHPCs). METHODS: GFP BM-chimera mice treated with or without bleomycin were used to assess the BM-derived cells. MEASUREMENTS AND MAIN RESULTS: GFP(+) cells in the chimera lung were found to be comprised of two distinct phenotypes: GFP(hi) and GFP(low) cells. The GFP(hi), but not GFP(low), population was significantly increased after bleomycin treatment. Flow-cytometric analysis and quantitative real-time polymerase chain reaction revealed that GFP(hi) cells exhibited phenotypic characteristics of CD11c(+) dendritic cells and macrophages. GFP(hi) cell conditioned media were chemotactic for fibroblasts obtained from fibrotic but not normal lung in vitro. Moreover, adoptive transfer of GFP(hi) cells exacerbated fibrosis in recipient mice, similar to that seen on adoptive transfer of BM-derived CD11c(+) cells from donor bleomycin-treated mice. Next, we evaluated the potential of LHPCs as the source of GFP(hi) cells. Isolation of LHPCs by flow sorting revealed enrichment in cKit(+)/Sca1(-)/Lin(-) cells, most of which were GFP(+) indicating their BM origin. The number of LHPCs increased rapidly after bleomycin treatment. Furthermore, stem cell factor induced LHPC proliferation, whereas granulocyte-macrophage-colony stimulating factor induced differentiation to GFP(hi) cells. CONCLUSIONS: BM-derived LHPCs with a novel phenotype could differentiate into GFP(hi) cells, which enhanced pulmonary fibrosis. Targeting this mobilized LHPCs might represent a novel therapeutic approach in chronic fibrotic lung diseases.
RATIONALE: Bone marrow (BM)-derived cells have been implicated in pulmonary fibrosis. However, their precise role in pathogenesis is incompletely understood. OBJECTIVES: To elucidate roles of BM-derived cells in bleomycin-induced pulmonary fibrosis, and clarify their potential relationship to lung hematopoietic progenitor cells (LHPCs). METHODS: GFP BM-chimera mice treated with or without bleomycin were used to assess the BM-derived cells. MEASUREMENTS AND MAIN RESULTS: GFP(+) cells in the chimera lung were found to be comprised of two distinct phenotypes: GFP(hi) and GFP(low) cells. The GFP(hi), but not GFP(low), population was significantly increased after bleomycin treatment. Flow-cytometric analysis and quantitative real-time polymerase chain reaction revealed that GFP(hi) cells exhibited phenotypic characteristics of CD11c(+) dendritic cells and macrophages. GFP(hi) cell conditioned media were chemotactic for fibroblasts obtained from fibrotic but not normal lung in vitro. Moreover, adoptive transfer of GFP(hi) cells exacerbated fibrosis in recipient mice, similar to that seen on adoptive transfer of BM-derived CD11c(+) cells from donorbleomycin-treated mice. Next, we evaluated the potential of LHPCs as the source of GFP(hi) cells. Isolation of LHPCs by flow sorting revealed enrichment in cKit(+)/Sca1(-)/Lin(-) cells, most of which were GFP(+) indicating their BM origin. The number of LHPCs increased rapidly after bleomycin treatment. Furthermore, stem cell factor induced LHPC proliferation, whereas granulocyte-macrophage-colony stimulating factor induced differentiation to GFP(hi) cells. CONCLUSIONS: BM-derived LHPCs with a novel phenotype could differentiate into GFP(hi) cells, which enhanced pulmonary fibrosis. Targeting this mobilized LHPCs might represent a novel therapeutic approach in chronic fibrotic lung diseases.
Authors: Lynne A Murray; Qingsheng Chen; Michael S Kramer; David P Hesson; Rochelle L Argentieri; Xueyang Peng; Mridu Gulati; Robert J Homer; Thomas Russell; Nico van Rooijen; Jack A Elias; Cory M Hogaboam; Erica L Herzog Journal: Int J Biochem Cell Biol Date: 2010-10-29 Impact factor: 5.085
Authors: Tianju Liu; Hyun Ah Baek; Hongfeng Yu; Ho Jin Lee; Byung-Hyun Park; Matthew Ullenbruch; Jianhua Liu; Taku Nakashima; Yoon Young Choi; Gary D Wu; Myoung Ja Chung; Sem H Phan Journal: J Immunol Date: 2011-05-20 Impact factor: 5.422
Authors: Michael A Gibbons; Alison C MacKinnon; Prakash Ramachandran; Kevin Dhaliwal; Rodger Duffin; Alexander T Phythian-Adams; Nico van Rooijen; Christopher Haslett; Sarah E Howie; A John Simpson; Nikhil Hirani; Jack Gauldie; John P Iredale; Tariq Sethi; Stuart J Forbes Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: Mauricio Rojas; Jianguo Xu; Charles R Woods; Ana L Mora; Willy Spears; Jesse Roman; Kenneth L Brigham Journal: Am J Respir Cell Mol Biol Date: 2005-05-12 Impact factor: 6.914
Authors: Shennea Marriott; Rubin S Baskir; Christa Gaskill; Swapna Menon; Erica J Carrier; Janice Williams; Megha Talati; Karen Helm; Catherine E Alford; Jonathan A Kropski; James Loyd; Lisa Wheeler; Joyce Johnson; Eric Austin; Eva Nozik-Grayck; Barbara Meyrick; James D West; Dwight J Klemm; Susan M Majka Journal: Am J Physiol Cell Physiol Date: 2014-10-15 Impact factor: 4.249
Authors: Stephen J Gurczynski; Megan C Procario; David N O'Dwyer; Carol A Wilke; Bethany B Moore Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-07-22 Impact factor: 5.464
Authors: Taku Nakashima; Tianju Liu; Biao Hu; Zhe Wu; Matthew Ullenbruch; Keitaro Omori; Lin Ding; Noboru Hattori; Sem H Phan Journal: Am J Respir Crit Care Med Date: 2019-10-15 Impact factor: 21.405
Authors: Lin Ding; Tianju Liu; Zhe Wu; Biao Hu; Taku Nakashima; Matthew Ullenbruch; Francina Gonzalez De Los Santos; Sem H Phan Journal: J Immunol Date: 2016-05-20 Impact factor: 5.422
Authors: Charles Reese; Rebecca Lee; Michael Bonner; Beth Perry; Jonathan Heywood; Richard M Silver; Elena Tourkina; Richard P Visconti; Stanley Hoffman Journal: Front Pharmacol Date: 2014-06-16 Impact factor: 5.810